Functional analysis of osteoclastogenesis inhibitor
Project/Area Number |
24810025
|
Research Category |
Grant-in-Aid for Research Activity Start-up
|
Allocation Type | Single-year Grants |
Research Field |
Chemical biology
|
Research Institution | Keio University |
Principal Investigator |
|
Project Period (FY) |
2012-08-31 – 2014-03-31
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Keywords | ケミカルバイオロジー / 破骨細胞 / 骨粗鬆症 |
Research Abstract |
Bone homeostasis is maintained by both osteoclasts and osteoblasts. Osteoporosis is one of the bone diseases caused by collapse of bone homeostasis. Inhibitors of osteoclast differentiation are expected as new therapeutic agents for osteoporosis. We have found that TPh A inhibits osteoclast differentiation from bone marrow macrophages. We investigated the effects on RANKL-induced osteoclast differentiation of 50 TPh A derivatives in order to obtain a compound that inhibits osteoclastogenesis at a lower concentration than TPh A. We found that SUK-39 is the most potent osteoclastogenesis inhibitor. Moreover, RT-PCR analysis showed that SUK-39 suppressed RANKL-induced DC-STAMP and its transcription factor, c-fos mRNA level. These results indicated that SUK-39 inhibited osteoclast fusion by inhibiting expression of c-fos and subsequent DC-STAMP mRNA expression. SUK-39 would be a bioprobe for understanding the mechanisms of osteoclast fusion.
|
Report
(3 results)
Research Products
(15 results)
-
-
[Journal Article] Determination of topological structure of ARL6ip1 in cells : Identification of the essential binding region of ARL6ip1 for conophylline2013
Author(s)
Kuroda, M., Funasaki, S., Saitoh, T., Sasazawa, Y., Nishiyama, S., Umezawa, K. & Simizu, S.
-
Journal Title
Related Report
Peer Reviewed
-
[Journal Article] Determination of topological structure of ARL6ip1 in cells: identification of the essential binding region of ARL6ip1 for conophylline2013
Author(s)
Kuroda, M., Funasaki, S., Saitoh, T., Sasazawa, Y., Nishiyama, S., Umezawa, K. & Simizu, S.
-
Journal Title
FEBS Letters
Volume: 587
Issue: 22
Pages: 3656-3660
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
[Presentation] Antitumor activity of xanthohumol, an valosin-containing inhibitor of protein2013
Author(s)
○Shikata, Y., Kanagaki, S., Sasazawa, Y., Tashiro, E., Yoshimaru, T., Komatsu, M., Katagiri, T., Imoto, M.
Organizer
AACR-NCI-EORTC International conference MOLECULAR TARGETS AND CANCER THERAPEUTICS
Place of Presentation
Boston
Related Report
-
-
-
[Presentation] Antitumor activity of xanthohumol, an inhibitor of valosin-containing protein.2013
Author(s)
Shikata, Y., Kanagaki, S., Sasazawa, Y., Tashiro, E., Yoshimaru, T., Komatsu, M., Katagiri, T., Imoto, M.
Organizer
AACR-NCI-EORTC International conference MOLECULAR TARGETS AND CANCER THERAPEUTICS
Place of Presentation
Boston
Related Report
-
-
-